EKFC Cystatin C
European Kidney Function Consortium
Cystatin C equation for adults, without sex or race terms
- Biomarkers
- Cystatin C
- Validated for
- 18+ years
- Inputs
- Age, Cystatin C
- Reports
- mL/min/1.73 m²
- Published
- 2023
The eGFR guide explains which equation the calculator suggests and indexed and absolute GFR.
Formula
As text: eGFR = 107.3 × (SCysC/Q)^α × [0.990^(Age-40) if Age>40]; α = -0.322 if SCysC/Q < 1, α = -1.132 if SCysC/Q ≥ 1
Constants
| Symbol | Meaning | Value |
|---|---|---|
107.3 | Base coefficient | |
| Median serum cystatin C reference | Age ≤ 50: 0.83mg/L Age > 50: 0.83 + 0.005 × (age − 50)mg/L | |
| Exponent (depends on SCysC/Q ratio) | SCysC/Q < 1: −0.322 SCysC/Q ≥ 1: −1.132 | |
Age factor | Age correction applied only when age > 40 | Age ≤ 40: 1 (no correction) Age > 40: 0.990^(age − 40) |
| Serum cystatin C (input) | mg/L | |
Age | Patient age (input) | years |
How it was developed
The EKFC creatinine equation was reused with rescaled cystatin C in place of rescaled creatinine, and the rescaling factor Q was estimated from cystatin C levels in 227,643 patients at Uppsala University Hospital, Sweden. The equation was validated against measured GFR in 12,832 adults: 11,231 from Europe, 1,093 from the United States and 508 from Africa.
Clinical notes
- Q is the median cystatin C of men and women combined
- Built on cystatin C assays standardized to ERM-DA471/IFCC
- Averaged with EKFC creatinine for the EKFC combined equation
Limitations
- Not validated in children
- Not validated in Black American or Asian cohorts
- Race- or sex-specific Q may be needed in some populations
- Cystatin C may be altered by adiposity, smoking, thyroid disease, glucocorticoid excess, inflammation
References
- Pottel H, Björk J, Rule AD, et al. Cystatin C-Based Equation to Estimate GFR without the Inclusion of Race and Sex. N Engl J Med. 2023;388(4):333-343. doi:10.1056/NEJMoa2203769
- Delanaye P, Cavalier E, Pottel H, Stehlé T. New and old GFR equations: a European perspective. Clin Kidney J. 2023;16(9):1375-1383. doi:10.1093/ckj/sfad039